Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 45 - Medicinal preparations containing active ingredients not provided for in groups
Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
10/2005
10/27/2005US20050239876 Tocopherol and tocotrienol aerosols
10/27/2005US20050239872 1,5-distributed pyrrolid-2-one derivatives for use as ep4 receptor agonists in the teatment of eye diseases such as glaucoma
10/27/2005US20050239867 Methods of using and compositions comprising PDE4 modulators for the treatment and management of pulmonary hypertension
10/27/2005US20050239863 Indole diterpene natural product and synthetic compound; Potassium channel blockers or a formulation thereof in the treatment of glaucoma and other conditions related to elevated intraocular pressure in the eye
10/27/2005US20050239857 Novel imidazoles
10/27/2005US20050239854 Body weight gain inhibitors
10/27/2005US20050239849 Substituted phenoxyacetic acids
10/27/2005US20050239824 Triple monoamine reuptake inhibitors for the treatment of chronic pain
10/27/2005US20050239821 Viral inhibitors
10/27/2005US20050239819 4-Oxoquinoline compounds and utilization thereof as hiv integrase inhibitors
10/27/2005US20050239813 Pharmaceutical compositions comprising fk506 derivatives and their use for the treatment of allergic diseases
10/27/2005US20050239789 2-(9-bromo-3,4,10,10a-tetrahydro-1H-pyrazino[1,2-a]indol-2-yl)-cyclobutanone; treating disorders of the central nervous system, damage to the central nervous system, cardiovascular disorders, gastrointestinal disorders, diabetes insipidus, obesity and sleep apnea
10/27/2005US20050239787 Novel maxi-k channel blockers, methods of use and process for making the same
10/27/2005US20050239759 Method of treatment of disease using an adenosine A1 receptor antagonist and an aldosterone inhibitor
10/27/2005US20050239753 Methods of inhibition of MMTV-like viruses
10/27/2005US20050239732 Immunostimulatory nucleic acid molecules
10/27/2005US20050239720 Combination of an agent that attenuates topoisomerase 1 activity and an agent that inhibits heat shock protein 90 for use in chemotherapy
10/27/2005US20050239698 placental growth factor (PLGF) capable of promoting neovascularization in the treatment of diseases and pathological alterations involving the cutaneous or subcutaneous connective tissue, scleroderma and skin ageing due to exposure to chemicals or solar radiation
10/27/2005US20050239686 Methods and compositions for optimization of oxygen transport by cell-free systems
10/27/2005US20050239685 Tissue volume reduction
10/27/2005US20050239170 Alpha-MSH related compounds and methods of use
10/27/2005US20050239169 Nucleotide sequences coding seladin-1polypeptide for use in treatment and prevention of alzheimer's disease
10/27/2005US20050239141 Modified antibody variable domains
10/27/2005US20050239138 Use of cardiac hormones to assess risk of cardiovascular complication from volume overload
10/27/2005US20050239131 Interactive system for presenting and eliminating substances
10/27/2005US20050239062 diagnosing Alzheimer's disease by measuring abundance of low-density lipoprotein receptor related protein-1 (LRP-1), abundance of transcripts thereof, or LRP-1 receptor activity and comparing with an age-matched control
10/27/2005US20050238739 Composition comprising a combination of calcium, cimicifugae racemosae rhizoma and vitamin D and its use as a pharmaceutical in conditions or disorders associated with or resulting from calcium deficiency or as a nutritional supplement
10/27/2005US20050238731 Composition and method for treating the effects of diseases and maladies of the upper digestive tract
10/27/2005US20050238729 biosynthesis inhibition via formaldehyde, glutaraldehyde, acrolein, quaternary amine compounds, cocodiamine, bronopol, 2-2-dibromo-3-nitrilo-propionamide; synergistic; cost efficiency
10/27/2005US20050238707 Method of cancer treatment
10/27/2005US20050238702 Medical composition containing photocrosslinkable chitosan derivative
10/27/2005US20050238693 Process for the preparation and activation of susbstances and a means of producing same
10/27/2005US20050238687 Methods and compositions of bioartificial kidney suitable for use in vivo or ex vivo
10/27/2005US20050238660 Cpg formulations and related methods
10/27/2005US20050238651 Treatment of inflammatory bowel disease
10/27/2005US20050238643 Modulation of lir function to treat rheumatoid arthritis
10/27/2005US20050238634 Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
10/27/2005US20050238631 Methods and compositions for preventing biofilm formation, reducing existing biofilms, and for reducing populations of bacteria
10/27/2005US20050238630 A Lactobacillus acidophilus strain in combination with a Propionibacterium freudenreichii strain, used to administer to ruminants to inhibit infrection by Escherichia coli, Escherichia coli O157: H7, Salmonella Spp., Salmonella typhimurium, Shigella Spp., and Staphylococcus aureus.
10/27/2005US20050238579 Human g protein-coupled receptor and modulators thereof for the treatment of ischemic heart disease and congestive heart failure
10/27/2005US20050238578 Administering anticarcinogenic agent and chelate complex of macrocyclic aminophosphonic acid and radionuclide such as samarium ethylenediaminetetramethylenephosphonic acid (EDTMP) to replace total body irradiation;antiproliferative agents; autoimmune, infectious, metabolic or genetic disorders
10/27/2005DE19964269B4 Verfahren zur Detektion des Proliferationspotentials von Zellen A process for the detection of the proliferation potential of cells
10/27/2005DE102004016683A1 Dauerhaft geschäumte Zusammensetzung Permanently foamed composition
10/27/2005CA2562694A1 Medicine comprising combination of acetylcholine esterase inhibitor and 5-substituted 3-oxadiazolyl-1,6-naphthyridin-2(1h)-one derivative
10/27/2005CA2562391A1 Solid pharmaceutical preparation
10/27/2005CA2562235A1 Piperazinylpiperidine derivatives as chemokine receptor antagonists
10/27/2005CA2505469A1 Drug delivery device comprising a bilayered polymeric coating having a cell cycle inhibitor that acts selectively at the g1 phase of the cell cycle incorporated into the first polymer coating layer
10/26/2005EP1589115A2 Polymorphisms of the human organic anion transporting polypeptide-C (OATP-C)
10/26/2005EP1589108A2 Methods and reagents for vaccination which generate a CD8 T cell immune response
10/26/2005EP1589006A1 Oxa- and thiazole derivatives useful as antidiabetics and antidiobesity agents
10/26/2005EP1588727A1 Drug/drug delivery systems for the prevention and treatment of vascular disease
10/26/2005EP1588726A1 Drug/drug delivery systems for the prevention and treatment of vascular disease
10/26/2005EP1588715A1 Agent improving proton-driven transporter-mediated absorption in digestive tract and process for producing the same
10/26/2005EP1588711A1 Composition trapping radicals in organism
10/26/2005EP1588706A2 Use of AT1 receptor antagonists or AT2 receptor modulator for the treatment of conditions or diseases associated with the increase of AT1 or AT2 receptors.
10/26/2005EP1588704A1 Alpha-aminoamide derivatives useful in the treatment of restless legs syndrome and addictive disorders
10/26/2005EP1588702A1 Azalide antibiotics for the topical treatment or prevention of ocular infections
10/26/2005EP1588701A2 Rapidly-decomposing dosage form for releasing nicotine in the oral cavity or in bodily cavities
10/26/2005EP1588692A1 Durable foamed composition
10/26/2005EP1588162A2 Hsc70 directed diagnostics and therapeutics for multidrug resistant neoplastic disease
10/26/2005EP1587913A1 New strains of bifidobacterium having the ability to produce glutamine
10/26/2005EP1587912A2 Methods of identifying and designing cell surface receptor inhibitors
10/26/2005EP1587789A2 Selective serotonin 2a/2c receptor inverse agonists as therapeutics for neurodegenerative diseases
10/26/2005EP1587584A1 Pharmaceutical combination for the prophylaxis or treatment of cardiovascular, cardiopulmonary, pulmonary or renal diseases
10/26/2005EP1587574A2 SELECTIVE 11b-HSD INHIBITORS AND METHODS FOR USE THEREOF
10/26/2005EP1587541A2 Compositions and methods of tolerizing a primate to an antigen
10/26/2005EP1587535A2 Title of the invention n-cyclohexylaminocarbonyl benzenesulfonamide derivatives
10/26/2005EP1587522A1 Attaining sexual wellness and health of the sexual vascular system with proanthocyanidins
10/26/2005EP1587519A2 Treatment of cancer with 2-deoxyglucose
10/26/2005EP1587512A2 Pde4 inhibitors for the treatment of neoplasms of lymphoid cells
10/26/2005EP1587506A2 Administration of capsaicinoids
10/26/2005EP1587498A1 Powder pharmaceutical compositions
10/26/2005EP1587486A2 Care or make-up composition comprising a 2-alkylideneaminooxyacetamide, its use for stimulating the growth of the hair or eyelashes and/or slowing down their loss
10/26/2005EP1587481A2 Sensitive proteasome sensor constructs and methods for their design and use
10/26/2005EP1587480A2 Polyhydroxylated pyrrolizidine
10/26/2005EP1587477A2 Odorless formulation for treating mucosal discontinuities
10/26/2005EP1587476A2 Novel compositions and methods in cancer
10/26/2005EP1587474A2 Fluoroalkoxy-substituted 1, 3-dihydro-isoindolyl compounds and their pharmaceutical uses
10/26/2005EP1587405A2 Novel compositions and methods for cancer
10/26/2005EP1534213A4 Water-based delivery systems
10/26/2005EP1390368B1 Disubstituted 7,9-guaninium halides as telomerase inhibitors
10/26/2005EP1299099B1 Novel use of (r)-(-)-2- 5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane and its physiologically acceptable salts
10/26/2005EP1280571B1 Delivery devices for treatment of vascular disease
10/26/2005EP1242048B1 Inhalation particles
10/26/2005EP1212081B1 Use of ace inhibitors in the prevention of congestive heart failure
10/26/2005EP1183229B1 Glucagon antagonists/inverse agonists
10/26/2005EP1140000B1 Cosmetic or dermatological composition containing an active principle stimulating hsp 32 protein synthesis in the skin and cosmetic treatment method
10/26/2005EP1137426B1 Breast cancer treatment using natural plant essential oils
10/26/2005EP1109559B1 Inhibition of pathogenic processes related to tissue trauma
10/26/2005EP1073415B1 Pharmaceutical compositions capable of being gelled
10/26/2005EP1037640B1 Administration of products of the 5-lipoxygenase metabolic pathway to enhance antimicrobial defense
10/26/2005EP1034793B1 Preventives/remedies for glaucoma
10/26/2005EP0896521B1 Composition, barrier film, and method for preventing contact dermatitis
10/26/2005EP0762880B1 Retroviral protease inhibitor combinations
10/26/2005CN1688715A Marker genes for determining renal toxicity
10/26/2005CN1688714A Diagnosis and treatment of the tuberous sclerosis pathway
10/26/2005CN1688603A Treatment and prophylaxis with 4-1BB-binding agents
10/26/2005CN1688572A Piperidinyl targeting compounds that selectively bind integrins
10/26/2005CN1688340A Methods and compositions for modulating T helper (TH) cell development and function
10/26/2005CN1688330A Method for cancer therapy using herbal extracts
1 ... 446 447 448 449 450 451 452 453 454 455 456 457 458 459 460 461 462 463 464 465 466 ... 1151